2-(3-吡啶基)硫代乙酰胺 | 51451-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(3-吡啶基)硫代乙酰胺
• 中文别名: 吡啶-3-硫代乙酰胺；3-吡啶基硫代乙酰胺；a-L-吡喃甘露糖苷,2-丙烯-1-基6-脱氧-3-O-(苯基甲基)-,2-乙酸酯
• 英文名称: 2-pyridin-3-yl-thioacetamide
• 英文别名: [3]pyridyl-thioacetic acid amide；[3]Pyridyl-thioessigsaeure-amid；pyridin-3-yl-thioacetamide；Pyridyl-(3)-essigsaeure-thioamid；3-Pyridineethanethioamide；2-pyridin-3-ylethanethioamide
• CAS: 51451-44-6
• 化学式: C₇H₈N₂S
• 分子量: 152.22
• InChiKey: VSBVYPLNYOJQEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(3-吡啶基)硫代乙酰胺 在 吡啶 作用下， 以 甲苯 、 xylene 为溶剂， 反应 3.0h， 生成 6-(3-Pyridylmethyl)-1,3,5-thiadiazine-2,4-dione
  参考文献：
  名称：

  Synthesis and in vitro antimicrobial activity of 6-substituted 2H-1,3,5-thiadiazine-2,4(3H)-diones

  摘要：

  A series of 6-substituted 2H-1,3,5-thiadiazine-2,4(3H)-diones (1a-m) was prepared by treatment of alkyl, aryl, and heterocyclic primary thioamides with phenoxycarbonyl isocyanate to give N-(phenoxycarbonyl)-N'-thioacylureas, which gave 1 upon heating in refluxing xylene solution or upon treatment with aqueous sodium carbonate solution followed by acidification. 1H NMR and infrared spectral evidence indicates that the 6-alkyl derivatives 1a,b,l,m exist predominately in the exocyclic alkylidene tautomeric form. The major product obtained from alkaline and acid hydrolysis of the 6-phenyl derivative 1c was found to be benzoic acid and benzoylurea, respectively. The majority of compounds 1a-m exhibited in vitro antifungal activity against Candida albicans and Trichophyton mentagrophytes. Several derivatives, 1b-d,h,j, displayed minimum inhibitory concentration values below 2 micrograms/mL against Trichophyton mentagrophytes. Four derivatives, 1c,e,g,h, inhibited the growth of Seratia marcesens, Staphylococcus aureus, and Staphylococcus epidermis in an in vitro sensitivity disk assay. 2-Furyl derivative 1h displayed antileukemic activity against P-388 lymphocytic leukemia.

  DOI：

  10.1021/jm00346a028
• 作为产物：
  描述：

  3-吡啶乙腈 在 氨 作用下， 生成 2-(3-吡啶基)硫代乙酰胺
  参考文献：
  名称：

  THE SYNTHESIS OF COMPOUNDS FOR THE CHEMOTHERAPY OF TUBERCULOSIS. IV. THE AMIDE FUNCTION¹

  摘要：

  DOI：

  10.1021/jo01370a009

文献信息

• Nonpeptide Arginine Vasopressin Antagonists for Both V1A and V2 Receptors: Synthesis and Pharmacological Properties of 4'-(1,4,5,6-Tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives and 4'-(5,6-Dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives.
  作者：Akira MATSUHISA、Nobuaki TANIGUCHI、Hiroyuki KOSHIO、Takeyuki YATSU、Akihiro TANAKA

  DOI：10.1248/cpb.48.21

  日期：——

  4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6- carbonyl)benzanilide and 4'-(5,6-dihydro-4H- thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide were synthesized and examined for AVP antagonist activity for both V1A and V2 receptors. As a result, it was found that the 4'-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbon yl)-2- phenylbenzanilide derivatives showed potent binding affinity

  精氨酸加压素（AVP）主要在外周具有双重作用，即通过V1A和V2受体进行血管收缩和水分吸收。它可能在多种疾病中起作用，包括充血性心力衰竭（CHF），高血压，肾脏疾病，水肿和低钠血症。我们基于对V1A和V2受体的阻断可能对CHF患者有益的假设，尝试开发出一系列针对V1A和V2受体的口服活性AVP拮抗剂。在此报告中，一系列与4'-（1,4,5,6-四氢咪唑并[4,5-d] [1]苯并氮杂氮杂-6-羰基）苯甲酰苯胺和4'-（5,6-合成了二氢-4H-噻唑并[5,4-d] [1]苯并ze庚因-6-羰基）苯甲酰苯并检查了其对V1A和V2受体的AVP拮抗剂活性。结果发现4'-（1,4,5，6-四氢咪唑并[4,5-d] [1]苯并ze庚因-6-碳基）-2-苯基苯甲腈衍生物对V1A和V2受体均显示强效结合亲和力。特别地，显示了4'-（2-甲基-1,4,5,6-四氢咪唑并[4,5-d] [1]苯并氮杂-6-
• Pyrid-2-one derivatives and methods of use
  申请人：——

  公开号：US20040147561A1

  公开（公告）日：2004-07-29

  Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疾病，如细胞增殖或凋亡介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该主题发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。
• Cephalosporin derivatives, their preparation and compositions containing
  申请人：Rhone-Poulenc Sante

  公开号：US04508717A1

  公开（公告）日：1985-04-02

  Cephalosporin derivatives of the formula: ##STR1## in which A is a single bond or a radical --CH.sub.2 --, --NH-- or --NHCO--, attached to the 3-position or 4-position of the pyridinio radical, R is a methyl, carboxymethyl, carbamoylmethyl, benzyl or allyl radical, R.sub.a, R.sub.b and R.sub.c are hydrogen atoms, or alternatively R.sub.a is carboxyl and R.sub.b and R.sub.c, which are identical or different, are hydrogen atoms or alkyl radicals, or together form an alkylene radical, and n equals 0 or 1, in their syn form, and also their addition salts with acids, metal salts and addition salts with nitrogen-containing bases are antibacterial agents having a broad spectrum of activity.

  公式为：##STR1##中的头孢菌素衍生物，其中A是连接到吡啶基的3位或4位的单键或基团--CH.sub.2 --，--NH--或--NHCO--，R是甲基、羧甲基、氨甲基、苄基或烯丙基基团，R.sub.a、R.sub.b和R.sub.c是氢原子，或者R.sub.a是羧基，R.sub.b和R.sub.c（相同或不同）是氢原子或烷基基团，或者共同形成一个烷基基团，n等于0或1，在它们的同形式中，以及它们与酸的加成盐、金属盐和与含氮碱的加成盐是具有广谱活性的抗菌剂。
• 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
  申请人：——

  公开号：US20040267017A1

  公开（公告）日：2004-12-30

  The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.

  本发明提供了一种带有3-吡啶基或4-异喹啉基取代基的新型噻唑，并提供了其制药组合物。本发明还提供了使用本发明化合物和制药组合物作为裂解酶抑制剂（例如17a-羟基酶-C17,20酶）的方法。本发明还提供了治疗患者癌症的方法，包括向患者投药本发明化合物或制药组合物。癌症可以是前列腺癌或乳腺癌等。
• Imidazo(1,2-a)pyridines, processes for their preparation and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0033094A1

  公开（公告）日：1981-08-05

  The invention relates to imidazo[1,2-a]pyridines of the general formula (wherein the substituents R2, R3, X, Z, T and Ar are as defined in the specification) and includes 2,3-dihydro-, 5,6,7,8-tetrahydro-, 2,3,5,6,7,8-hexahydro-anaiogues and salts of such compounds. The invention also relates to processes for preparing such compounds and to pharmaceutical compositions containing them. The compounds are antisecretory and cytoprotective agents and are particularly useful in the treatment of ulcer diseases.

  本发明涉及通式如下的咪唑并[1,2-a]吡啶（其中取代基 R2、R3、X、Z、T 和 Ar 如说明书所定义 (其中取代基 R2、R3、X、Z、T 和 Ar 如说明书中所定义），包括 2,3-二氢-、5,6,7,8-四氢-、2,3,5,6,7,8-六氢-安乃近和这类化合物的盐。本发明还涉及制备这类化合物的工艺和含有这类化合物的药物组合物。这些化合物是抗分泌物和细胞保护剂，尤其适用于治疗溃疡病。